Exagen Inc. (NYSE:XGN) Director James L. L. Tullis sold 15,000 shares of the stock in a transaction dated Friday, September 11th. The shares were sold at an average price of $12.40, for a total value of $186,000.00. Following the completion of the transaction, the director now owns 38,745 shares of the company’s stock, valued at $480,438. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.
XGN opened at $12.50 on Wednesday. The business has a 50 day simple moving average of $13.90 and a two-hundred day simple moving average of $14.04. Exagen Inc. has a one year low of $10.29 and a one year high of $29.86.
Exagen (NYSE:XGN) last posted its quarterly earnings results on Tuesday, July 28th. The company reported ($0.27) earnings per share for the quarter, topping the consensus estimate of ($0.77) by $0.50. The company had revenue of $8.95 million during the quarter, compared to analysts’ expectations of $4.82 million.
Several research firms recently commented on XGN. Cantor Fitzgerald began coverage on Exagen in a research note on Monday, June 1st. They set an “overweight” rating and a $20.00 target price for the company. Zacks Investment Research cut Exagen from a “buy” rating to a “hold” rating in a research report on Saturday, August 1st.
Exagen Company Profile
Exagen Inc operates as a commercial-stage diagnostics company, develops and markets products for the diagnosis, prognosis, and monitoring of patients affected by autoimmune rheumatic diseases (ARDs). Its lead product includes Avise SLE+CT, a proprietary diagnostic test that provides an enhanced solution for patients with a range of ARDs, such as systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), Sjögren's syndrome, and scleroderma, as well as other disorders, including fibromyalgia.
Featured Story: What is Liquidity?
Receive News & Ratings for Exagen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exagen and related companies with MarketBeat.com's FREE daily email newsletter.